Background and Purpose: Aggregation and adherence of platelets to vascular endothelium are increased during diabetes mellitus, and thus responses of cerebral arteries to products released by platelets may have important implications for the pathogenesis of stroke during diabetes. The goal of this study was to determine whether responses of the basilar artery to products released by platelets are altered during diabetes.
S
erotonin, adenosine 5'-diphosphate (ADP), and thromboxane are important vasoactive substances that are released during platelet aggregation. 1 " 3 Diabetes mellitus appears to increase platelet activation. 4 -7 In light of findings that suggest that there is an increased incidence of stroke during diabetes mellitus, 8 - 1 ' we speculated that abnormalities of platelets during diabetes, coupled to altered responses of cerebral blood vessels to products released by platelets, may be a contributing factor in the pathogenesis of stroke during diabetes.
In recent studies, we were the first to report that in vivo responses of cerebral (pial) arterioles to products released by platelets (i.e., ADP and serotonin) are altered during diabetes. 12 - 13 Dilatation of pial arterioles in response to ADP was profoundly impaired during diabetes. 1213 In addition, serotonin produced dilatation of pial arterioles in nondiabetic rats but constriction of From the Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha, Neb.
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Received December 19, 1991 ; final revision received June 8, 1992; accepted June 22, 1992. pial arterioles in diabetic rats. 12 Constriction of pial arterioles in response to the thromboxane analogue U-46619 was similar in nondiabetic and diabetic rats. Thus, our previous findings 1213 suggest that responses of small cerebral blood vessels to ADP and serotonin are altered during diabetes.
See Editorial Comment, p 1503
There appear to be important regional differences in the responses of cerebral vessels to many vasoactive agents. Responses of the basilar artery are different than those of pial arterioles to many vasoactive substances.
14 " 17 Thus, the goal of this study was to determine whether in vivo responses of a large cerebral artery (i.e., the basilar artery) to products that are released by platelets are altered during diabetes mellitus.
Materials and Methods

Induction of Diabetes
Young adult male rats weighing 200-220 g were divided randomly into nondiabetic and diabetic groups. All rats were housed in mesh (hanging) cages and had access to food and water ad libitum. One group of rats was injected with 50-60 mg/kg i.p. streptozotocin to induce diabetes. The second (nondiabetic) group of rats was injected with the vehicle. Blood samples for measurement of blood glucose concentration were obtained at 2 weeks and 1 month after injection of streptozotocin by guest on April 12, 2017 http://stroke.ahajournals.org/ Downloaded from or vehicle and on the day of the experiment. Blood glucose concentration was determined by using a Glucoscan Meter (Lifescan, Inc., Mountain View, Calif.). Rats with a blood glucose concentration of >300 mg/dl were considered diabetic. We have used these methods to produce diabetes mellitus in rats previously.
121318
Preparation of Animals
Rats were prepared for studies at 4-5 months after injection of streptozotocin or vehicle. Rats were anesthetized with 50 mg/kg body wt i.p. pentobarbital sodium, and a tracheotomy was performed. The animals were ventilated mechanically with room air and supplemental oxygen. A catheter was inserted into a femoral vein for injection of drugs, and a femoral artery was cannulated for measurement of arterial pressure. Skeletal muscle paralysis was induced with 5-10 mg/kg i.v. gallamine triethiodide. Supplemental anesthesia was administered at a dose of 10-20 mg/kg/hr intravenously. No differences were observed between nondiabetic and diabetic rats with regard to amount of pentobarbital (milligrams per kilogram body weight) required to induce anesthesia. In addition, no differences existed between nondiabetic and diabetic rats with regard to the amount of anesthesia or paralytic agent required as supplement.
After placement of all catheters, the rat was placed in a head holder in the supine position. Then, a craniotomy was made in the bone of the ventral brain stem. The dura was incised to expose the basilar artery. We 1920 and others 21 have used this method to expose the basilar artery previously.
The cranial window was suffused with artificial cerebrospinal fluid at 38°C and bubbled continuously to maintain gases within normal limits. Blood gases were monitored and maintained within normal limits throughout the experiment.
Diameter of the basilar artery was measured on-line using a video image-shearing device (model 908, Instrumentation for Physiology and Medicine, Inc., San Diego, Calif.).
Experimental Protocol
The basilar artery preparation was allowed to equilibrate for 30 minutes after the craniotomy. Then, we examined responses of the basilar artery in nondiabetic and diabetic rats to 10 and 100 fiM ADP, 0.01, 0.1, and 1.0 /xM serotonin, and 0.1 and 1.0 /xM U-46619. Drugs were mixed in artificial cerebrospinal fluid during superfusion over the cranial window. Diameter of the basilar artery was measured immediately before application of the agonists and every 30-45 seconds for 5 minutes during application of the agonists. Steady-state responses to the agonists were reached within 2 minutes after application, and diameter of the basilar artery returned to the control value within 2-5 minutes after application of the agonists was stopped.
Statistical Analysis
An unpaired t test was used to compare values between nondiabetic and diabetic rats; p=0.05 was considered to be significant. 
Results
Control Conditions
Mean arterial pressure was similar in nondiabetic (134±6 mm Hg) and diabetic (123±5 mm Hg, p>0.05 versus nondiabetic) rats. Baseline diameter of the basilar artery also was similar in nondiabetic (251 ±14 jj,m) and diabetic (282±14 (im, p>0.05 versus nondiabetic) rats. Blood glucose concentration was higher in diabetic (364±15 mg/dl) than in nondiabetic (90±8 mg/dl, p<0.05 versus diabetic) rats, and body weight was lower in diabetic (287+16 g) than in nondiabetic (425±19 g, p<0.05 versus diabetic) rats.
Responses to Products Released by Platelets
Application of ADP produced only minimal changes in diameter of the basilar artery in nondiabetic and diabetic rats (Figure 1 ). The magnitude of the change was similar in nondiabetic and diabetic rats (Figure 1) . At 10 and 100 /uM ADP dilated the basilar artery by 1±1% and 2±2%, respectively, in nondiabetic rats and by 2±1% and 2±2%, respectively, in diabetic rats (p>0.05 versus nondiabetic). Thus, responses of the basilar artery to a vasodilator released by platelets are minimal in nondiabetic and diabetic rats.
Serotonin produced dose-related constriction of the basilar artery in nondiabetic and diabetic rats ( Figure  2 ). The magnitude of the constriction was similar in nondiabetic and diabetic rats (Figure 2 ). At 0.01, 0.1, and 1.0 /u-M serotonin constricted the basilar artery by 6±2%, 22±4%, and 33±4%, respectively, in nondiabetic rats and by 14±4%, 27+4%, and 41±4%, respectively, in diabetic rats (p>0.05 versus nondiabetic).
U-46619 produced similar dose-related constriction of the basilar artery in nondiabetic and diabetic rats (Figure 3 basilar artery by 17±3% and 28±3%, respectively, in nondiabetic rats and by 21 ±4% and 30±4%, respectively, in diabetic rats (/?>0.05 versus nondiabetic).
Discussion This is the first study to examine in vivo responses of the basilar artery to products released by platelets in nondiabetic and diabetic rats. The major finding is that responses of the basilar artery to ADP, serotonin, and the thromboxane analogue U-46619 are not altered during diabetes mellitus.
Response to ADP
Investigators have shown that ADP produces relaxation of large cerebral arteries in vitro. 22 - 23 In addition, we have shown that ADP, at concentrations used in the present study, produces dilatation of pial arterioles in rats in vivo.
-
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- 24 Furthermore, we have recently shown that ADP-induced dilatation of pial arterioles is related to the release of nitric oxide or a substance with the pharmacological properties of nitric oxide. 24 We found that inhibitors of nitric oxide synthase (AT G -monomethyl-L-arginine and JV w -nitro-L-arginine) block dilatation of pial arterioles in response to ADP. 24 In the present studies we elected to examine responses of the basilar artery to concentrations of ADP that we have used in previous studies. 12 ' 13 ' 24 In the present study, ADP produced only minimal changes in diameter of the basilar artery in nondiabetic and diabetic rats. This finding is in agreement with previous findings 19 - 25 that ADP, at concentrations used in the present study, produces only minimal dilatation of the basilar artery in rats.
Responses of the basilar artery to ADP in nondiabetic and diabetic rats differ from that reported for pial arterioles. We have reported that ADP produces a marked dilatation of pial arterioles in nondiabetic rats that is impaired in diabetic rats. 12 ' 13 In addition, we have shown that impaired responses of pial arterioles in diabetic rats in response to ADP could be restored toward those observed in nondiabetic rats by treatment with indomethacin and SQ 29548. 13 Thus, the mechanism of impaired responses of pial arterioles during diabetes mellitus appears to be related to the production of a cyclooxygenase constrictor substance and more precisely related to the activation of the prostaglandin H 2 /thromboxane A 2 receptor. The findings of the present study suggest that there are important regional differences in responses of cerebral blood vessels to ADP; ADP produces marked dilatation of pial arterioles but has minimal effects on diameter of the basilar artery.
The inability of ADP to produce significant dilatation of the basilar artery in nondiabetic and diabetic rats is probably not related to a nonspecific impairment of vasodilatation in nondiabetic and diabetic rats. We have shown previously that nitroglycerin produces marked dilatation of the basilar artery.
19
- 20 The inability of ADP to produce significant dilatation of the basilar artery also is not related to a damaged endothelium in nondiabetic rats. We have shown previously that acetylcholine produces marked dilatation of the basilar artery in normal rats. 20 Thus, minimal dilatation of the basilar artery in response to ADP in nondiabetic rats cannot be explained by altered endothelial function.
Response to Serotonin
Several studies have examined the effects of diabetes on responses of peripheral blood vessels to serotonin. Investigators have reported that constrictor responses to serotonin are increased in the mesenteric artery in streptozotocin-induced diabetic rats 26 and the aorta of alloxan-induced diabetic rabbits. 27 In contrast, other investigators have reported that diabetes decreases contractile responses to serotonin in mesenteric arterioles of streptozotocin-induced diabetic mice 28 and in the aorta of streptozotocin-induced diabetic rats. 29 In addition, other investigators have reported that diabetes does not alter responses of the aorta 29 or carotid artery 30 to serotonin in alloxan-induced diabetic rabbits and of the coronary arteries 31 in streptozotocin-induced diabetic rats. Thus, responses of noncerebral blood vessels to serotonin during diabetes mellitus are conflicting.
Investigators also have examined the effects of diabetes on responses of cerebral (pial) blood vessels to serotonin. Rosenblum and Levasseur 32 found that constriction of pial arterioles in response to serotonin was similar in nondiabetic and streptozotocin-induced diabetic mice. In recent studies, we examined responses of pial arterioles to serotonin in streptozotocin-induced diabetic rats. 12 In contrast to the previous study, 32 we 12 found that serotonin produced dilatation of pial arterioles in nondiabetic rats but constriction of pial arterioles in diabetic rats. We speculated that reversal of the responses to serotonin from vasodilatation to vasoconstriction in diabetic rats was related to an alteration in endothelial function. Our evidence concerning the endothelium-dependent nature of responses of cerebral blood vessels to serotonin, however, is indirect. We have not examined responses of cerebral arterioles to serotonin before and after inhibition of endothelium-derived relaxing factor (i.e., nitric oxide) and thus do not know the precise role of the endothelium in modulating responses of cerebral blood vessels to serotonin. If responses to serotonin are not modulated by the release of substances from the endothelium and if serotonin, when released from platelets, is metabolized by the endothelium before reaching vascular muscle, then topical application of serotonin, as used in the present studies, may have relevance to the effects of serotonin on cerebral vessels via release from the parenchyma and/or nerves. One previous study has examined the effects of diabetes on responses of the basilar artery to serotonin. 27 These investigators, using in vitro methodology, found that serotonin produced similar contraction of the basilar artery in nondiabetic and alloxan-induced diabetic rabbits. The findings of the present study are in agreement with this previous study. 27 We found that constriction of the basilar artery in vivo in response to serotonin was similar in nondiabetic and diabetic rats. The findings of the present study extend those of the previous study 27 by examining responses to other important products released by platelets (i.e., ADP and thromboxane).
Response to U-46619
No studies have examined the effects of diabetes on responses of the basilar artery in vivo to the thromboxane analogue U-46619. In the present study we found that constriction of the basilar artery in response to U-46619 was similar in nondiabetic and diabetic rats. This finding is in contrast to that reported previously for peripheral vascular beds. 3334 In one study 34 investigators report that constrictor responses of blood-perfused hind limbs were less in 2-week diabetic rats than in nondiabetic rats in response to U-46619. In the other study 33 investigators report that constriction of the isolated perfused kidney in response to U-46619 was increased in diabetic compared with nondiabetic rats.
The discrepancy between the present study and previous studies 33 ' 34 is not clear but may be related to the role of the endothelium in responses of blood vessels to thromboxane. Contraction of canine and porcine coronary arteries in response to U-46619 is similar in endothelium-intact and -denuded preparations. 35 In contrast, contraction of rabbit coronary arteries 36 and rat aorta 37 in response to thromboxane appears to be modulated by the endothelium. In the present study, we did not examine the role of the endothelium in responses of the basilar artery to U-46619 in nondiabetic and diabetic rats. Since we found that constriction of the basilar artery in response to U-46619 was similar in nondiabetic and diabetic rats, we speculated that if responses of the basilar artery to U-46619 were modulated by the endothelium, then this pathway may not be altered during diabetes mellitus. If, however, responses to U-46619 are not modulated by the endothelium and if U-46619, when released from platelets, is metabolized by the endothelium before reaching vascular muscle, then topical application of U-46619, as used in the present studies, may have relevance to the effects of thromboxane on cerebral vessels via release from cerebral parenchyma.
In conclusion, ADP produced only minimal changes in diameter of the basilar artery in nondiabetic and diabetic rats. In addition, constriction of the basilar artery in response to serotonin and the thromboxane analogue U-46619 was similar in nondiabetic and diabetic rats.
